

# National Oesophago-Gastric Cancer Audit

## The Hillingdon Hospitals NHS Foundation Trust

RM Partners West London, Cancer Alliance

### Management of High Grade Dysplasia patients

Time period: 2018-22

		Cancer Alliance	National
Number of High Grade Dysplasia patients in audit	48		1120
		Cancer Alliance	National
<b>Method of Diagnosis</b>			
– First diagnosis confirmed by second pathologist	N/A	95.5%	90.0%
<b>Treatment planning</b>			
– HGD plan discussed at MDT	N/A	95.8%	93.0%
– Treatment plan for active treatment	N/A	85.0%	82.0%
<b>First treatment</b>			
– Endoscopic therapy (such as endoscopic resection)	N/A	85.0%	78.0%
– Surveillance	N/A	2.5%	11.0%

NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.

## Management of oesophago-gastric cancer patients

Time period: 2020-2022

	Organisation		National
Number of oesophago-gastric (OG) cancer patients in audit	65		19,865
Case ascertainment for OG cancer (%)	75-84%		
<b>Method of Diagnosis</b>			
– Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations	14	21.8%	13.1%
– Patients with referral source reported as unknown	1	1.5%	1.4%
<b>Pre-treatment staging of cancer</b>			
– Patients having staging CT scan recorded	N/A		94.0%
<b>Treatment planning</b>			
– Patients having a plan for curative treatment	27	41.5%	37.2%
– Patients having a plan for non-curative treatment	38	58.5%	62.8%
– Patients with non-curative plans having chemotherapy or radiotherapy	N/A		34.7%